New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 14, 2013
16:09 EDTBLUEBluebird Bio reports Q2 EPS ($2.13), may not compare consensus (35c)
Reports Q2 revenue $6.33M, consensus $4.48M.
News For BLUE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 17, 2014
11:49 EDTBLUEPiper Jaffray healthcare analysts to hold an analyst/industry conference call
Subscribe for More Information
07:16 EDTBLUEMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
November 13, 2014
07:30 EDTBLUECredit Suisse to hold a conference
Healthcare Conference is being held in Scottsdale, Arizona on November 10-13 with webcasted company presentations to begin on November 13 at 11 am; not all company presentations may be webcasted. Webcast Link
November 12, 2014
07:08 EDTBLUEbluebird bio reports Q3 EPS (61c), consensus (50c)
Reports Q3 revenue $6.37M, consensus $6.21M.
November 10, 2014
07:08 EDTBLUEbluebird bio names James DeTore as CFO, treasurer
Subscribe for More Information
November 6, 2014
11:40 EDTBLUEbluebird bio data still maturing, says Piper Jaffray
Subscribe for More Information
10:59 EDTBLUEbluebird bio provides development update, says Cowen
Cowen said bluebird bio's additional data from the Northstar study showed one new patient is responding more slowly than the two betahalassemia patients who responded more quickly and became transfusion independent. The analyst said the important news is that the patient is responding and bluebird will present additional data at ASH
10:41 EDTBLUEbluebird bio falls after additional data from Northstar study disclosed
Shares of bluebird bio (BIO) are moving lower in early trading after an abstract containing additional details from a company study was posted to the website of the American Society of Hematology, or ASH. WHAT'S NEW: The presentation, entitled "Initial Results from the Northstar Study: A Phase 1/2 Study of Gene Therapy for ‑Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex Vivo with [LentiGlobin BB305 Drug Product]," is scheduled to be presented orally on December 8 at the ASH meeting. A summary of the results states that, as of 31 July, 3 subjects have undergone HSC collection and ex-vivo LentiGlobin BB305 gene transfer. One subject has undergone myeloablation and drug product infusion. Last June, Bluebird reported that following a single infusion of LentiGlobin gene therapy, two B-thal patients started producing functional hemoglobin and within 10 and 12 days, respectively, were able to halt blood transfusions, noted Adam Feuerstein of TheStreet. The third beta-thal patient treated with Bluebird's gene therapy is not improving as quickly, the abstract indicates. PRICE ACTION: Shares of bluebird bio are down 4.6% to $37.22 in early trading following the posting of the abstract.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use